No writing assistance was utilized in the production of this manuscript. Alirocumab (formerly SAR236553/REGN727) is a monoclonal antibody directed at PCSK9 that showed good efficacy in Phase II ...
A total of 204 subjects were screened and 103 were randomized, 52 to the alirocumab group and 51 to the ezetimibe group. All 103 randomized subjects received study treatment (the safety population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback